224 related articles for article (PubMed ID: 36648737)
1. Cost-Effectiveness of Neoadjuvant Pembrolizumab Plus Chemotherapy Followed by Adjuvant Single-Agent Pembrolizumab for High-Risk Early-Stage Triple-Negative Breast Cancer in the United States.
Huang M; A Fasching P; Haiderali A; Xue W; Yang C; Pan W; Zhou ZY; Hu P; Chaudhuri M; Le Bailly De Tilleghem C; Cappoen N; O'Shaughnessy J
Adv Ther; 2023 Mar; 40(3):1153-1170. PubMed ID: 36648737
[TBL] [Abstract][Full Text] [Related]
2. Cost-Effectiveness of Neoadjuvant Pembrolizumab plus Chemotherapy Followed by Adjuvant Pembrolizumab in Patients with High-Risk, Early-Stage, Triple-Negative Breast Cancer in Switzerland.
Favre-Bulle A; Huang M; Haiderali A; Bhadhuri A
Pharmacoecon Open; 2024 Jan; 8(1):91-101. PubMed ID: 37999854
[TBL] [Abstract][Full Text] [Related]
3. Cost-Effectiveness Analysis of Pembrolizumab as an Adjuvant Treatment of Resected Stage IIB or IIC Melanoma in the United States.
Zhang S; Bensimon AG; Xu R; Jiang R; Greatsinger A; Zhang A; Fukunaga-Kalabis M; Krepler C
Adv Ther; 2023 Jul; 40(7):3038-3055. PubMed ID: 37191852
[TBL] [Abstract][Full Text] [Related]
4. Cost-Effectiveness Analysis of Pembrolizumab as an Adjuvant Treatment of Renal Cell Carcinoma Post-nephrectomy in the United States.
Lai Y; Bensimon AG; Gao E; Bhattacharya R; Xu R; Chevure J; Imai K; Haas NB
Clin Genitourin Cancer; 2023 Oct; 21(5):612.e1-612.e11. PubMed ID: 37137809
[TBL] [Abstract][Full Text] [Related]
5. Cost-effectiveness of pembrolizumab for the adjuvant treatment of resected high-risk stage III melanoma in the United States.
Bensimon AG; Zhou ZY; Jenkins M; Song Y; Gao W; Signorovitch J; Krepler C; Liu FX; Wang J; Aguiar-Ibáñez R
J Med Econ; 2019 Oct; 22(10):981-993. PubMed ID: 31012765
[No Abstract] [Full Text] [Related]
6. Cost Effectiveness of Adding Pembrolizumab to Platinum and Fluoropyrimidine-Based Chemotherapy as First-Line Treatment for Advanced Esophageal Cancer: A US Healthcare Payer's Perspective.
Qu T; Zhang S; Zhong Y; Meng Y; Guo H; Joo S; Enzinger PC
Pharmacoeconomics; 2022 Dec; 40(12):1247-1259. PubMed ID: 36241842
[TBL] [Abstract][Full Text] [Related]
7. Event-free Survival with Pembrolizumab in Early Triple-Negative Breast Cancer.
Schmid P; Cortes J; Dent R; Pusztai L; McArthur H; Kümmel S; Bergh J; Denkert C; Park YH; Hui R; Harbeck N; Takahashi M; Untch M; Fasching PA; Cardoso F; Andersen J; Patt D; Danso M; Ferreira M; Mouret-Reynier MA; Im SA; Ahn JH; Gion M; Baron-Hay S; Boileau JF; Ding Y; Tryfonidis K; Aktan G; Karantza V; O'Shaughnessy J;
N Engl J Med; 2022 Feb; 386(6):556-567. PubMed ID: 35139274
[TBL] [Abstract][Full Text] [Related]
8. Cost-Effectiveness of Pembrolizumab as an Adjuvant Treatment in Colombia for Melanoma Patients with Lymph Node Involvement After Complete Resection.
Lopez-Vinueza C; Urrego-Reyes J; Gutierrez FRS; Wurcel V; Zhang S; Jiang S; Jiang R; Zambrano Harvey A; Dhankhar P; Sawhney B; Baluni G; Jain S; Bhadra D
Adv Ther; 2023 Jun; 40(6):2836-2854. PubMed ID: 37129772
[TBL] [Abstract][Full Text] [Related]
9. The cost effectiveness of pembrolizumab versus chemotherapy or atezolizumab as second-line therapy for advanced urothelial carcinoma in the United States.
Slater RL; Lai Y; Zhong Y; Li H; Meng Y; Moreno BH; Godwin JL; Frenkl T; Sonpavde GP; Mamtani R
J Med Econ; 2020 Sep; 23(9):967-977. PubMed ID: 32412387
[No Abstract] [Full Text] [Related]
10. Cost effectiveness of pembrolizumab plus lenvatinib compared with chemotherapy for treating previously treated advanced endometrial cancer in Sweden.
Ralph L; Young K; Upadhyay N; Prabhu VS; Ljungcrantz C; Massaad R; Xu R; Giertz A; Merchant A; Orlowski R; Duska L
J Med Econ; 2024; 27(1):483-491. PubMed ID: 38470404
[TBL] [Abstract][Full Text] [Related]
11. Cost-effectiveness of neoadjuvant pembrolizumab plus chemotherapy with adjuvant pembrolizumab for early-stage non-small cell lung cancer in the United States.
Tian W; Niu L; Wang Z; Lu R; Xiao G; Deng F; Tanzhu G; Zhou R
Front Immunol; 2023; 14():1268070. PubMed ID: 37822936
[TBL] [Abstract][Full Text] [Related]
12. Cost-effectiveness analysis of nivolumab plus ipilimumab plus two cycles of platinum-doublet chemotherapy versus platinum-doublet chemotherapy alone for first-line treatment of stage IV or recurrent non-small cell lung cancer in the United States.
Polyzoi M; Sandhu H; Maervoet J; Yuan Y; Chaudhary MA; Varol N; Lee A; Dale P; Jones C; Lubinga SJ; Penrod JR
J Med Econ; 2022; 25(1):660-668. PubMed ID: 35658806
[TBL] [Abstract][Full Text] [Related]
13. An Economic Evaluation of Pembrolizumab Versus Other Adjuvant Treatment Strategies for Resected High-Risk Stage III Melanoma in the USA.
Bensimon AG; Zhou ZY; Jenkins M; Song Y; Gao W; Signorovitch J; Krepler C; Scherrer E; Wang J; Aguiar-Ibáñez R
Clin Drug Investig; 2020 Jul; 40(7):629-643. PubMed ID: 32418051
[TBL] [Abstract][Full Text] [Related]
14. Cost-Effectiveness Analysis of Venetoclax in Combination with Azacitidine Versus Azacitidine Monotherapy in Patients with Acute Myeloid Leukemia Who are Ineligible for Intensive Chemotherapy: From a US Third Party Payer Perspective.
Pratz KW; Chai X; Xie J; Yin L; Nie X; Montez M; Iantuono E; Downs L; Ma E
Pharmacoeconomics; 2022 Aug; 40(8):777-790. PubMed ID: 35696071
[TBL] [Abstract][Full Text] [Related]
15. Pembrolizumab Plus Chemotherapy Followed by Pembrolizumab in Patients With Early Triple-Negative Breast Cancer: A Secondary Analysis of a Randomized Clinical Trial.
Takahashi M; Cortés J; Dent R; Pusztai L; McArthur H; Kümmel S; Denkert C; Park YH; Im SA; Ahn JH; Mukai H; Huang CS; Chen SC; Kim MH; Jia L; Li XT; Tryfonidis K; Karantza V; Iwata H; Schmid P
JAMA Netw Open; 2023 Nov; 6(11):e2342107. PubMed ID: 37966841
[TBL] [Abstract][Full Text] [Related]
16. Cost-effectiveness analysis of pembrolizumab versus standard-of-care chemotherapy for first-line treatment of PD-L1 positive (>50%) metastatic squamous and non-squamous non-small cell lung cancer in France.
Chouaid C; Bensimon L; Clay E; Millier A; Levy-Bachelot L; Huang M; Levy P
Lung Cancer; 2019 Jan; 127():44-52. PubMed ID: 30642550
[TBL] [Abstract][Full Text] [Related]
17. Cost-effectiveness analysis of pembrolizumab plus chemotherapy as first-line therapy for extensive-stage small-cell lung cancer.
Liu Q; Tan C; Yi L; Wan X; Peng L; Li J; Luo X; Zeng X
PLoS One; 2021; 16(11):e0258605. PubMed ID: 34780478
[TBL] [Abstract][Full Text] [Related]
18. Pembrolizumab for Early Triple-Negative Breast Cancer.
Schmid P; Cortes J; Pusztai L; McArthur H; Kümmel S; Bergh J; Denkert C; Park YH; Hui R; Harbeck N; Takahashi M; Foukakis T; Fasching PA; Cardoso F; Untch M; Jia L; Karantza V; Zhao J; Aktan G; Dent R; O'Shaughnessy J;
N Engl J Med; 2020 Feb; 382(9):810-821. PubMed ID: 32101663
[TBL] [Abstract][Full Text] [Related]
19. Cost effectiveness of pembrolizumab vs chemotherapy as first-line treatment for metastatic NSCLC that expresses high levels of PD-L1 in Switzerland.
Bhadhuri A; Insinga R; Guggisberg P; Panje C; Schwenkglenks M
Swiss Med Wkly; 2019 Dec; 149():w20170. PubMed ID: 31880807
[TBL] [Abstract][Full Text] [Related]
20. Cost-effectiveness of pembrolizumab compared with chemotherapy in the US for women with previously treated deficient mismatch repair or high microsatellite instability unresectable or metastatic endometrial cancer.
Thurgar E; Gouldson M; Matthijsse S; Amonkar M; Marinello P; Upadhyay N; Nwankwo C; Aguiar-Ibáñez R
J Med Econ; 2021; 24(1):675-688. PubMed ID: 33866938
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
